Австралія - англійська - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 43.27 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - ovarian cancer, breast cancer, non small cell lung cancer, pancreatic cancer

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: benzyl alcohol; mannitol; water for injections - vincristine sulphate injection is used in the treatment of cancers of the blood (eg. leukaemia or lymphomas), breast, head and neck or lung. it may be used to treat multiple myeloma (a cancer of plasma cells) and it may also be used in the treatment of some cancers in children. it may be used in a blood disorder known as idiopathic thrombocytopenic purpura (itp) after other treatments have not been successful. vincristine sulphate injection may be given alone or in combination with other anti-cancer medicines.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 43.27 mg/ml - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - gemcitabine is indicated for treatment of locally advanced or metastatic bladder cancer in combination with cisplatin. gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc). gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelian ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first line therapy. gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 43.27 mg/ml - injection, concentrated - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - gemcitabine is indicated for treatment of locally advanced or metastatic bladder cancer in combination with cisplatin. gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc). gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelian ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first line therapy. gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 43.27 mg/ml - injection, concentrated - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - gemcitabine is indicated for treatment of locally advanced or metastatic bladder cancer in combination with cisplatin. gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc). gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelian ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first line therapy. gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - docetaxel, quantity: 10 mg/ml - injection, solution - excipient ingredients: citric acid; polysorbate 80; macrogol 300; ethanol absolute - breast cancer: - for the treatment of patients with locally advanced or metastatic breast cancer. - in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. - in combination with xeloda? (capecitabine) is indicated for the treatment of patients with advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. non-small cell lung cancer: - for the treatment of patients with locally advanced or metastatic non-small cell lung cancer in monotherapy or in combination with platinum derivatives. ovarian cancer: - for the treatment of metastatic carcinoma of the ovary after failure of first-line or subsequent chemotherapy. prostate cancer: - in combination with prednisone or prednisolone is indicated for the treatment of patients with androgen-independent (hormone-refractory) metastatic prostate cancer. squamous cell carcinoma of the head and neck: - indicated as monotherapy in the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after failure of a previous chemotherapy regimen.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - docetaxel, quantity: 10 mg/ml - injection, solution - excipient ingredients: citric acid; polysorbate 80; macrogol 300; ethanol absolute - breast cancer: - for the treatment of patients with locally advanced or metastatic breast cancer. - in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. - in combination with xeloda? (capecitabine) is indicated for the treatment of patients with advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. non-small cell lung cancer: - for the treatment of patients with locally advanced or metastatic non-small cell lung cancer in monotherapy or in combination with platinum derivatives. ovarian cancer: - for the treatment of metastatic carcinoma of the ovary after failure of first-line or subsequent chemotherapy. prostate cancer: - in combination with prednisone or prednisolone is indicated for the treatment of patients with androgen-independent (hormone-refractory) metastatic prostate cancer. squamous cell carcinoma of the head and neck: - indicated as monotherapy in the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after failure of a previous chemotherapy regimen.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - docetaxel, quantity: 10 mg/ml - injection, solution - excipient ingredients: citric acid; polysorbate 80; macrogol 300; ethanol absolute - breast cancer: - for the treatment of patients with locally advanced or metastatic breast cancer. - in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. - in combination with xeloda? (capecitabine) is indicated for the treatment of patients with advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. non-small cell lung cancer: - for the treatment of patients with locally advanced or metastatic non-small cell lung cancer in monotherapy or in combination with platinum derivatives. ovarian cancer: - for the treatment of metastatic carcinoma of the ovary after failure of first-line or subsequent chemotherapy. prostate cancer: - in combination with prednisone or prednisolone is indicated for the treatment of patients with androgen-independent (hormone-refractory) metastatic prostate cancer. squamous cell carcinoma of the head and neck: - indicated as monotherapy in the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after failure of a previous chemotherapy regimen.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - pentostatin, quantity: 10 mg - injection, powder for - excipient ingredients: mannitol; sodium hydroxide; hydrochloric acid - smpc - pentostatin is indicated as single agent therapy in the treatment of adult patients with hairy cell leukaemia. label - nipent is an anticancer medicine used to treat adults with hairy cell leukaemia, a form of cancer affecting lymphocytes (white blood cells important for fighting invading viruses and bacteria)

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - pentostatin, quantity: 10 mg - injection, powder for - excipient ingredients: mannitol; hydrochloric acid; sodium hydroxide - nipent is indicated as single-agent treatment for both untreated and alpha-interferon-refractory hairy cell leukemia patients with active disease as defined by clinically significant anemia,neutropenia, thrombocytopenia, or disease-related symptoms.